Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Lung Cancer | Research article

Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI

Authors: Guofu Chen, Baiqiang Dong, Guoping Shan, Xiuqin Zhang, Huarong Tang, Yuchen Li, Zhenhua Wang, Wei Xu, Gang Xu, Guiming Yan, Feiyan Zhang, Xiao Hu, Jun Yang, Yujin Xu, Ming Chen, Jin Wang

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

An accurate, reproducible, and comfortable immobilization device is essential for stereotactic radiotherapy (SBRT) in patients with lung cancer. This study compared thermoplastic masks (TMP) and vacuum cushion (VCS) system to assess the differences in interfraction and intrafraction setup accuracy and the impact of body mass index (BMI) with respect to the immobilization choice.

Methods

This retrospective study was conducted on patients treated with lung SBRT between 2012 and 2015 at the Zhejiang cancer hospital. The treatment setup accuracy was analyzed in 121 patients. A total of 687 cone beam computed tomography (CBCT) scans before treatment and 126 scans after treatment were recorded to determine the uncertainties, and plan target volume margins. Data were further stratified and analyzed by immobilization methods and patients’ BMI. The t-test (Welch) was used to assess the differences between the two immobilization systems when stratified by the patients’ BMI.

Results

For patients with BMI ≥ 24, the mean displacements for the TMP and VCS systems were 1.4 ± 1.2 vs. 2.4 ± 2.0 mm at medial-lateral (ML) direction (p < 0.001); 2.0 ± 1.9 vs. 2.0 ± 1.9 mm at cranial-caudal (CC) direction (p = 0.917); and 2.4 ± 1.4 vs. 2.6 ± 2.1 mm at anterior-posterior (AP) direction, (p = 0.546). The rate of acceptable errors increased dramatically when immobilized by TMP. In the case of patients with BMI < 24, the mean displacements for the TMP and VCS systems were 1.8 ± 1.4 vs. 2.1 ± 1.8 mm at ML direction (p = 0.098); 2.9 ± 2.3 vs. 2.2 ± 2.2 mm at CC direction (p = 0.001); and 1.8 ± 1.8 vs. 2.3 ± 2.0 mm at CC direction, (p = 0.006). The proportion of acceptable errors increased after immobilization by VCS. No difference was detected in the intrafraction setup error by different immobilization methods.

Conclusions

The immobilization choice of SBRT for lung tumors depends on the BMI of the patients. For patients with BMI ≥ 24, TMP offers a better reproducibility with significantly less interfractional setup displacement than VCS, resulting in fewer CBCT scans. However, VCS may be preferred over TMP for the patients with BMI < 24. Therefore, an optimal immobilization system needs to be considered in different BMI groups for lung SBRT.
Literature
1.
go back to reference Chi A, Liao Z, Nguyen N, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94:1–11.CrossRef Chi A, Liao Z, Nguyen N, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94:1–11.CrossRef
2.
go back to reference Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88:359–67.CrossRef Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88:359–67.CrossRef
3.
go back to reference Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109:1–7.CrossRef Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109:1–7.CrossRef
4.
go back to reference Murray L, Ramasamy S, Lilley J, Snee M, Clarke K, Musunuru H, et al. Stereotactic ablative radiotherapy (SABR) in patients with medically inoperable peripheral early stage lung Cancer: outcomes for the first UK SABR cohort. Clin Oncol (R Coll Radiol). 2016;28:4–12.CrossRef Murray L, Ramasamy S, Lilley J, Snee M, Clarke K, Musunuru H, et al. Stereotactic ablative radiotherapy (SABR) in patients with medically inoperable peripheral early stage lung Cancer: outcomes for the first UK SABR cohort. Clin Oncol (R Coll Radiol). 2016;28:4–12.CrossRef
5.
go back to reference Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011;101:255–9.CrossRef Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011;101:255–9.CrossRef
6.
go back to reference Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–100.CrossRef Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–100.CrossRef
7.
go back to reference Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–31.CrossRef Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–31.CrossRef
8.
go back to reference Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–70.CrossRef Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–70.CrossRef
9.
go back to reference Li W, Purdie T, Taremi M, Fung S, Brade A, Cho B, et al. Effect of immobilization and performance status on intrafraction motion for stereotactic lung radiotherapy: analysis of 133 patients. Int J Radiat Oncol Biol Phys. 2011;81:1568–75.CrossRef Li W, Purdie T, Taremi M, Fung S, Brade A, Cho B, et al. Effect of immobilization and performance status on intrafraction motion for stereotactic lung radiotherapy: analysis of 133 patients. Int J Radiat Oncol Biol Phys. 2011;81:1568–75.CrossRef
10.
go back to reference Navarro-Martin A, Cacicedo J, Leaman O, Sancho I, García E, Navarro V, et al. Comparative analysis of thermoplastic masks versus vacuum cushions in stereotactic body radiotherapy. Radiat Oncol. 2015;10:176.CrossRef Navarro-Martin A, Cacicedo J, Leaman O, Sancho I, García E, Navarro V, et al. Comparative analysis of thermoplastic masks versus vacuum cushions in stereotactic body radiotherapy. Radiat Oncol. 2015;10:176.CrossRef
11.
go back to reference Rossi M, Peulen H, Belderbos J, Sonke J. Intrafraction motion in stereotactic body radiation therapy for non-small cell lung Cancer: intensity modulated radiation therapy versus volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys. 2016;95:835–43.CrossRef Rossi M, Peulen H, Belderbos J, Sonke J. Intrafraction motion in stereotactic body radiation therapy for non-small cell lung Cancer: intensity modulated radiation therapy versus volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys. 2016;95:835–43.CrossRef
12.
go back to reference Sio T, Jensen A, Miller R, Fong de los Santos L, Hallemeier C, Foster N, et al. Influence of patient's physiologic factors and immobilization choice with stereotactic body radiotherapy for upper lung tumors. J Appl Clin Med Phys. 2014;15:4931.PubMed Sio T, Jensen A, Miller R, Fong de los Santos L, Hallemeier C, Foster N, et al. Influence of patient's physiologic factors and immobilization choice with stereotactic body radiotherapy for upper lung tumors. J Appl Clin Med Phys. 2014;15:4931.PubMed
13.
go back to reference van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004;14:52–64.CrossRef van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004;14:52–64.CrossRef
14.
go back to reference Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung Cancer. JAMA. 2010;303:1070–6.CrossRef Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung Cancer. JAMA. 2010;303:1070–6.CrossRef
15.
go back to reference Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy (SBRT) for early stage peripheral non-small cell lung Cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88:1092–9.CrossRef Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy (SBRT) for early stage peripheral non-small cell lung Cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88:1092–9.CrossRef
16.
go back to reference Hayashi S, Tanaka H, Kajiura Y, Ohno Y, Hoshi H. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol. 2014;9:138.CrossRef Hayashi S, Tanaka H, Kajiura Y, Ohno Y, Hoshi H. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol. 2014;9:138.CrossRef
17.
go back to reference Holt A, van Vliet-Vroegindeweij C, Mans A, Belderbos JS, Damen EM. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensity-modulated radiotherapy techniques. Int J Radiat Oncol Biol Phys. 2011;81:1560–7.CrossRef Holt A, van Vliet-Vroegindeweij C, Mans A, Belderbos JS, Damen EM. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensity-modulated radiotherapy techniques. Int J Radiat Oncol Biol Phys. 2011;81:1560–7.CrossRef
18.
go back to reference Weyh A, Konski A, Nalichowski A, Maier J, Lack D. Lung SBRT: dosimetric and delivery comparison of RapidArc, TomoTherapy, and IMR. J Appl Clin Med Phys. 2013;14:4065.CrossRef Weyh A, Konski A, Nalichowski A, Maier J, Lack D. Lung SBRT: dosimetric and delivery comparison of RapidArc, TomoTherapy, and IMR. J Appl Clin Med Phys. 2013;14:4065.CrossRef
19.
go back to reference Li R, Han B, Meng B, Maxim PG, Xing L, Koong AC, et al. Clinical implementation of intrafraction cone beam computed tomography imaging during lung tumor stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87:917–23.CrossRef Li R, Han B, Meng B, Maxim PG, Xing L, Koong AC, et al. Clinical implementation of intrafraction cone beam computed tomography imaging during lung tumor stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87:917–23.CrossRef
20.
go back to reference Richmond ND, Pilling KE, Peedell C, Shakespeare D, Walker CP. Positioning accuracy for lung stereotactic body radiotherapy patients determined by on-treatment cone-beam CT imaging. Br J Radiol. 2012;85:819–23.CrossRef Richmond ND, Pilling KE, Peedell C, Shakespeare D, Walker CP. Positioning accuracy for lung stereotactic body radiotherapy patients determined by on-treatment cone-beam CT imaging. Br J Radiol. 2012;85:819–23.CrossRef
21.
go back to reference Mathew L, Swaminath A, Szabo J, Wierzbicki M. Sci-Thur AM: planning - 06: planning target volume margin suitability in lung stereotactic body radiation therapy: a preliminary evaluation using cone-beam computed tomography. Med Phys. 2012;39:4620.CrossRef Mathew L, Swaminath A, Szabo J, Wierzbicki M. Sci-Thur AM: planning - 06: planning target volume margin suitability in lung stereotactic body radiation therapy: a preliminary evaluation using cone-beam computed tomography. Med Phys. 2012;39:4620.CrossRef
Metadata
Title
Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI
Authors
Guofu Chen
Baiqiang Dong
Guoping Shan
Xiuqin Zhang
Huarong Tang
Yuchen Li
Zhenhua Wang
Wei Xu
Gang Xu
Guiming Yan
Feiyan Zhang
Xiao Hu
Jun Yang
Yujin Xu
Ming Chen
Jin Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5767-1

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine